Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats

Levodopa (L-dopa) is the dominating therapy drug for exogenous dopaminergic substitution and can alleviate most of the manifestations of Parkinson’s disease (PD), but long-term therapy is associated with the emergence of L-dopa-induced dyskinesia (LID). Evidence points towards an involvement of Glyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Cheng-long, Lin, Jing-Ya, Wang, Mei-Hua, Zhang, Yu, Zhang, Su-fang, Wang, Xi-Jin, Liu, Zhen-Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800499/
https://www.ncbi.nlm.nih.gov/pubmed/26997328
http://dx.doi.org/10.1038/srep23527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800499/
https://www.ncbi.nlm.nih.gov/pubmed/26997328
http://dx.doi.org/10.1038/srep23527

Ejemplares similares